Document is current
Any future updates will be listed below
-
Authors
Li, Yifang
Hunter, Alex
Wakeel, Miqdad M.
Sun, Guizhi
Lau, Ricky W. K.
Broughton, Brad R. S.
Pino, Ivan E. Oyarce
Deng, Zihao
Zhang, Tingfang
Murthi, Padma
Del Borgo, Mark P.
Widdop, Robert E.
Polo, Jose M.
Ricardo, Sharon D.
Samuel, Chrishan S. https://orcid.org/0000-0003-0295-4214
-
Funding
Funding for this research was provided by:
National Health and Medical Research Council (GNT1156446, GNT2019014)
- License Information
-
More Information
Article History
Received: 6 August 2024
Accepted: 9 October 2024
First Online: 23 October 2024
Declarations
:
: The work performed on the IRI model was approved (on 04/08/2022) under the application: Monash Animal Research Platform (MARP)/2022/29417, titled ‘Cell and diet-based therapies in experimental kidney disease’, by the Monash University Animal Ethics Committee. The work performed on the HS model was approved (on 23/08/2021) under the application: MARP/2021/30019, titled ‘Evaluation of engineered mesenchymal stem cells in an experimental model of hypertension’, by the Monash University Animal Ethics Committee.
: Not applicable.
: All authors have no conflicts of interest to disclose.
